Weekly Respiratory Research Analysis
This week’s respiratory literature highlighted three high-impact advances: (1) a large randomized trial shows oral ensitrelvir prevents symptomatic COVID-19 when given as postexposure prophylaxis to household contacts with a strong safety profile; (2) translational immunology work identifies an HLA‑E–NKG2A checkpoint that suppresses NK-cell clearance of senescent fibroblasts and demonstrates NK-directed approaches can reverse fibrosis in preclinical models; and (3) a pneumatically actuated lung
Summary
This week’s respiratory literature highlighted three high-impact advances: (1) a large randomized trial shows oral ensitrelvir prevents symptomatic COVID-19 when given as postexposure prophylaxis to household contacts with a strong safety profile; (2) translational immunology work identifies an HLA‑E–NKG2A checkpoint that suppresses NK-cell clearance of senescent fibroblasts and demonstrates NK-directed approaches can reverse fibrosis in preclinical models; and (3) a pneumatically actuated lung microphysiological model reveals compressive airway mechanics drive subepithelial fibrosis and abnormal vascular remodelling in asthma, providing a translational testbed for antifibrotic therapies.
Selected Articles
1. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
Double-blind, randomized, placebo-controlled trial in 2,041 household contacts showed that a 5-day course of oral ensitrelvir started within 72 hours of the index case symptom onset reduced symptomatic, PCR-confirmed COVID-19 by day 10 from 9.0% to 2.9% (risk ratio 0.33). Adverse events and serious adverse events were similar to placebo and no COVID-19–related hospitalizations or deaths occurred.
Impact: First high-quality RCT demonstrating effective oral postexposure prophylaxis against COVID-19 in household contacts, with a favorable safety profile — potentially practice-changing for outbreak and household management.
Clinical Implications: Supports consideration of ensitrelvir for postexposure prophylaxis in eligible household contacts within 72 hours of index symptom onset, especially for those at higher risk for severe disease; warrants guideline discussion and real-world effectiveness monitoring across variants and vaccination statuses.
Key Findings
- Modified ITT population (mITT) included 1030 ensitrelvir vs 1011 placebo recipients.
- Primary outcome (symptomatic PCR-confirmed COVID-19 by day 10): 2.9% vs 9.0% (RR 0.33; 95% CI 0.22–0.49; P<0.001).
- Adverse events: 15.1% ensitrelvir vs 15.5% placebo; serious adverse events 0.2% each; no COVID-19 hospitalizations/deaths.
2. Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Translational multi-omic and functional studies identify NKG2A as a dominant inhibitory checkpoint on NK cells in fibrotic lungs and show senescent fibroblasts express HLA‑E to evade NK clearance. Mechanistic cocultures and in vivo models demonstrate that targeting the HLA‑E–NKG2A axis restores NK antifibrotic activity and can reverse fibrosis in preclinical systems.
Impact: Provides a mechanistic, druggable checkpoint axis (HLA‑E–NKG2A) that explains persistence of fibrotic stroma and demonstrates proof-of-concept for NK-based antifibrotic immunotherapy — a clear translational inflection point for fibrotic lung disease.
Clinical Implications: Supports early-phase clinical development of NKG2A blockade and NK adoptive strategies in pulmonary fibrosis, with HLA‑E/NKG2A expression as candidate companion biomarkers for patient selection.
Key Findings
- NKG2A is the predominant inhibitory checkpoint receptor on NK cells in fibrotic lungs (single-cell and spectral flow data).
- Senescent fibroblasts express HLA‑E and suppress NK function via HLA‑E–NKG2A interactions in coculture assays.
- Targeting the axis restores NK antifibrotic activity and reverses fibrosis in preclinical models.
3. Mechanical force-induced tissue remodelling in a clinically relevant microphysiological model of asthmatic human lungs.
A pneumatically actuated lung-on-chip reproducing distal airway constriction demonstrates that compressive mechanical loading drives subepithelial fibrosis and increased airway vascularity. Proteomics identified mediators of abnormal remodelling and pharmacologic modulation was feasible in the system, offering a translational platform for testing antifibrotic and vascular-modulating therapies.
Impact: Establishes a human-relevant mechanobiology platform that causally links airway mechanics to fibrosis and vascular change, enabling mechanism-informed preclinical screening and target prioritization for asthma remodeling therapies.
Clinical Implications: Although preclinical, the model prioritizes subepithelial fibrosis as a therapeutic focus and can accelerate translational testing of antifibrotic and anti-angiogenic agents for airway remodelling in asthma.
Key Findings
- A soft-actuated airway-on-chip reproduced distal airway constriction and compressive force-induced fibrotic remodelling.
- Subepithelial fibrosis was identified as a key driver of increased airway vascularity in asthma.
- Proteomic mediators were identified and pharmacologic modulation was feasible within the system.